Worldwide Cancer Research Menu

Understanding how Acute Myeloid Leukaemia cells avoid dying

  • Researcher: Professor David MacEwan
  • Institution: University of East Anglia
  • Award Amount: £193,106 for 3 years from April 2012
  • Cancer Type: Leukaemia
Understanding how Acute Myeloid Leukaemia cells avoid dying
Acute Myeloid Leukaemia (AML) is rare and is most common in people over 65 years old. Current treatments are mainly only suitable for younger and fitter patients, meaning there is a need for better treatments for many patients. Professor MacEwan and his team have recently identified a molecule called Nrf2 which is able to help the cell avoid dying, even when treated with chemotherapy drugs but it is still not clear exactly how it can do this. One theory is that acute myeloid leukaemia cells have high levels of Nrf2. Professor MacEwan is now using his Worldwide Cancer Research grant and samples from patients to fully investigate how Nrf2 is able to cause this protective effect on the acute myeloid leukaemia cells. He hopes that his results could aid the development of better treatments for acute myeloid leukaemia patients in the future.
Showing: All projects

The Research That Is Happening Right Now

Explore current projects to see how far-reaching our research is from a global perspective.

Projects per page: 31020

Our Impact

See the difference our research projects make.

Our philosophy is very simple: if we believe a project can make a difference in the fight against cancer then we will award a grant to make it happen. We’re not interested in national borders or any kind of geographical bias, just the most promising proposals. And that’s the very reason we ask t...
Read more
Life in the Lab
Supporters often ask us what type of projects their donations are funding. What does a typical day in the life of a cancer researcher look like? To answer these questions and give you an insight into the vital work your support helps us to fund, we've put together this short video....
Read more